EBS
Neutral signalScored 2026-10-12 Drivers: trend, fundamentals. Insiders: neutral. Moteurs : tendance, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Emergent BioSolutions Inc.
- Nom
- Emergent BioSolutions Inc.
- Secteur
- Healthcare
- Industrie
- Drug Manufacturers - Specialty & Generic
- Bourse
- NYSE
- Capitalisation
- $319.4M
- Employés
- 900
- PDG
- Joseph C. Papa Jr.
- Site web
- https://www.emergentbiosolutions.com
- Marché
- AQSTCMPSCRVSESPROLMAORGO
Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and naturally occurring events, including chemical, biological, radiological, nuclear, and explosives (CBRNE) incidents, emerging infectious diseases, travel-related health risks, and acute emergency care situations. The company's current product portfolio features essential vaccines and treatments such as BioThrax for anthrax and ACAM2000 for smallpox. It also offers Botulism Antitoxin Heptavalent, vaccinia immune globulin intravenous to manage smallpox vaccine complications, and inhalational anthrax therapies like raxibacumab and Anthrasil. Other key offerings include reactive skin decontamination lotion kits, the Trobigard combination drug-device auto-injector, NARCAN nasal spray for emergency opioid overdose reversal, Vivotif, an oral typhoid fever vaccine, and Vaxchora, a single-dose oral cholera vaccine. Emergent is also actively engaged in developing a robust pipeline of future solutions. This includes AP003 (a multidose naloxone nasal spray), AP007 (a sustained-release nalmefene injection for opioid use disorder), AV7909 (an anthrax vaccine), CGRD-001 (a pralidoxime chloride/atropine auto-injector), CHIKV VLP (a chikungunya virus vaccine), COVID-HIG (for SARS-CoV2 treatment), EGRD-001 (a diazepam auto-injector), SIAN (a cyanide poisoning antidote), and UniFlu (a universal influenza vaccine). Furthermore, the company extends its expertise through comprehensive contract development and manufacturing services (CDMO). These services cover drug substance and product manufacturing, packaging, along with technology transfer and advanced process and analytical development. Emergent BioSolutions Inc., founded in 1998, is headquartered in Gaithersburg, Maryland.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 17 800 titres (~126 202,00 $ US)
- Insiders
- DeGolyer Donald W
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$145,792
Avg sell (VWAP, 90d window) $7.01 vs last close $7.18 (+2.4%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$145,792 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-07
- Liquidity
- Thin $7,586,227/day · 20d vol
- Last synced
-
2026-10-15 21:10:20
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-07 | DeGolyer Donald W | Sell · S · 10b5-1 | 17,800 | $7.09 | $126,202 | Form 4 |
| 2026-10-01 | Williams Paul Anthony | Sell · S · 10b5-1 | 3,000 | $6.53 | $19,590 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2024-12-11 | Stephen Cohen | Sale (Full) | $1,001 - $15,000 |
| 2021-11-05 | Josh Gottheimer | Sale (Full) | $1,001 - $15,000 |
| 2021-10-18 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2021-09-15 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2021-02-23 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2020-11-24 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2020-07-30 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2020-06-30 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2020-06-26 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2020-06-19 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2020-06-15 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2020-03-26 | Stephen Cohen | Sale (Full) | $1,001 - $15,000 |
| 2019-08-29 | Stephen Cohen | Sale (Full) | $15,001 - $50,000 |
Signal
Neutral signalScored 2026-10-12 Drivers: trend, fundamentals. Insiders: neutral. Moteurs : tendance, fondamentaux. Initiés : neutre.
EBS presents a compelling financial recovery story with strong liquidity (90) and improving fundamentals (85), including a return to profitability and meaningful deleveraging in 2025.
The first sentence of the analysis written for EBS on 2026-10-12 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $146K) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $146K) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Supports a bullish reading. Current ratio 5.01 · operating margin 15%
Suggested stop 5.30, nearest stored support minus 0.5 ATR(26.2% under the last close). Reward/risk to the next stored resistance is 0.14. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 47.2% | 36.0% | 34.3% | 42.3% | 44.7% | |
| Ebit Margin | 19.1% | -5.0% | -16.0% | -9.8% | 21.8% | |
| Ebitda Margin | 32.0% | 5.4% | -4.1% | 3.0% | 28.7% | |
| Operating Profit Margin | 14.8% | -10.4% | -69.2% | -15.2% | 19.2% | |
| Pretax Profit Margin | 11.1% | -13.7% | -69.7% | -19.6% | 17.1% | |
| Continuous Operations Profit Margin | 7.1% | -18.3% | -72.5% | -18.9% | 12.4% | |
| Net Profit Margin | 7.1% | -18.3% | -72.5% | -18.9% | 12.4% | |
| Bottom Line Profit Margin | 7.1% | -18.3% | -72.5% | -18.9% | 12.4% | |
| Current Ratio | 5.011 | 3.687 | 1.043 | 0.985 | 3.395 | |
| Quick Ratio | 2.414 | 1.767 | 0.538 | 0.700 | 2.474 | |
| Solvency Ratio | 0.186 | -0.090 | -0.541 | -0.038 | 0.255 | |
| Cash Ratio | 1.554 | 0.613 | 0.172 | 0.523 | 1.541 | |
| Price To Earnings Ratio | 12.612 | -2.656 | -0.162 | -2.799 | 10.602 | |
| Price To Earnings Growth Ratio | -0.099 | 0.035 | -0.001 | 0.014 | -0.363 | |
| Forward Price To Earnings Growth Ratio | -0.099 | 0.035 | -0.001 | 0.014 | -0.363 | |
| Price To Earnings Diluted Ratio | 13.290 | -2.656 | -0.162 | -2.799 | 10.707 | |
| Price To Earnings Diluted Growth Ratio | -0.106 | 0.035 | -0.001 | 0.014 | -0.377 | |
| Price To Book Ratio | 1.265 | 1.049 | 0.189 | 0.426 | 1.443 | |
| Price To Sales Ratio | 0.890 | 0.486 | 0.117 | 0.529 | 1.311 | |
| Price To Free Cash Flow Ratio | 4.217 | 14.153 | -0.476 | -3.947 | 24.200 | |
| Price To Operating Cash Flow Ratio | 3.876 | 8.632 | -0.596 | -17.351 | 7.243 | |
| Debt To Assets Ratio | 0.434 | 0.487 | 0.472 | 0.450 | 0.294 | |
| Debt To Equity Ratio | 1.095 | 1.400 | 1.325 | 1.028 | 0.540 | |
| Debt To Capital Ratio | 0.523 | 0.583 | 0.570 | 0.507 | 0.351 | |
| Long Term Debt To Capital Ratio | 0.523 | 0.579 | 0.407 | 0.244 | 0.334 | |
| Financial Leverage Ratio | 2.523 | 2.878 | 2.808 | 2.282 | 1.835 | |
| Working Capital Turnover Ratio | 1.537 | 4.493 | 216.351 | 2.547 | 2.078 | |
| Operating Cash Flow Ratio | 1.290 | 0.361 | -0.317 | -0.028 | 0.859 | |
| Operating Cash Flow Sales Ratio | 0.230 | 0.056 | -0.197 | -0.031 | 0.181 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.919 | 0.610 | 1.250 | 4.396 | 0.299 | |
| Debt Service Coverage Ratio | 3.503 | 0.121 | -0.144 | 0.041 | 5.926 | |
| Interest Coverage Ratio | 1.858 | -1.531 | -8.264 | -4.558 | 9.896 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 21.741 | -0.499 | -0.035 | 8.586 | |
| Operating Cash Flow Coverage Ratio | 0.298 | 0.087 | -0.240 | -0.024 | 0.369 | |
| Capital Expenditure Coverage Ratio | 12.362 | 2.563 | -3.998 | -0.294 | 1.427 | |
| Dividend Paid And Capex Coverage Ratio | 12.362 | 2.563 | -3.998 | -0.294 | 1.427 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 4.321 | 19.139 | -20.265 | 40.455 | 5.140 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 47.2% | ▲11.2% | ▲6.3% |
| Ebit Margin | 19.1% | ▲24.1% | ▲17.1% |
| Ebitda Margin | 32.0% | ▲26.6% | ▲19.0% |
| Operating Profit Margin | 14.8% | ▲25.2% | ▲27.0% |
| Pretax Profit Margin | 11.2% | ▲24.8% | ▲26.1% |
| Continuous Operations Profit Margin | 7.1% | ▲25.3% | ▲25.1% |
| Net Profit Margin | 7.1% | ▲25.3% | ▲25.1% |
| Bottom Line Profit Margin | 7.1% | ▲25.3% | ▲25.1% |
| Current Ratio | 5.011 | ▲1.325 | ▲2.187 |
| Quick Ratio | 2.414 | ▲0.646 | ▲0.835 |
| Solvency Ratio | 0.186 | ▲0.277 | ▲0.232 |
| Cash Ratio | 1.554 | ▲0.941 | ▲0.673 |
| Price To Earnings Ratio | 12.612 | ▲15.268 | ▲9.092 |
| Price To Earnings Growth Ratio | -0.099 | ▼-0.134 | ▼-0.016 |
| Forward Price To Earnings Growth Ratio | -0.099 | ▼-0.134 | ▼-0.016 |
| Price To Earnings Diluted Ratio | 13.290 | ▲15.946 | ▲9.614 |
| Price To Earnings Diluted Growth Ratio | -0.106 | ▼-0.141 | ▼-0.019 |
| Price To Book Ratio | 1.265 | ▲0.216 | ▲0.391 |
| Price To Sales Ratio | 0.890 | ▲0.405 | ▲0.223 |
| Price To Free Cash Flow Ratio | 4.217 | ▼-9.936 | ▼-3.412 |
| Price To Operating Cash Flow Ratio | 3.876 | ▼-4.756 | ▲3.515 |
| Debt To Assets Ratio | 0.434 | ▼-0.053 | ▲0.006 |
| Debt To Equity Ratio | 1.095 | ▼-0.306 | ▲0.017 |
| Debt To Capital Ratio | 0.523 | ▼-0.061 | ▲0.016 |
| Long Term Debt To Capital Ratio | 0.523 | ▼-0.056 | ▲0.105 |
| Financial Leverage Ratio | 2.523 | ▼-0.355 | ▲0.058 |
| Working Capital Turnover Ratio | 1.537 | ▼-2.956 | ▼-43.864 |
| Operating Cash Flow Ratio | 1.290 | ▲0.929 | ▲0.857 |
| Operating Cash Flow Sales Ratio | 0.230 | ▲0.173 | ▲0.182 |
| Free Cash Flow Operating Cash Flow Ratio | 0.919 | ▲0.309 | ▼-0.576 |
| Debt Service Coverage Ratio | 3.502 | ▲3.382 | ▲1.613 |
| Interest Coverage Ratio | 1.858 | ▲3.389 | ▲2.378 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | ▼-21.741 | ▼-5.958 |
| Operating Cash Flow Coverage Ratio | 0.298 | ▲0.211 | ▲0.200 |
| Capital Expenditure Coverage Ratio | 12.362 | ▲9.799 | ▲9.950 |
| Dividend Paid And Capex Coverage Ratio | 12.362 | ▲9.799 | ▲9.950 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 4.321 | ▼-14.818 | ▼-5.437 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $661.3M | $506.7M | $122.9M | $591.7M | $2.33B | |
| Enterprise value | $1.03B | $1.08B | $871.4M | $1.38B | $2.62B | |
| EV / Sales | 1.38x | 1.04x | 0.83x | 1.23x | 1.48x | |
| EV / Op. cash flow | 6.03x | 18.45x | -4.22x | -40.34x | 8.16x | |
| EV / Free cash flow | 6.56x | 30.26x | -3.38x | -9.18x | 27.27x | |
| EV / EBITDA | 4.32x | 19.14x | -20.27x | 40.45x | 5.14x | |
| Net debt / EBITDA | 1.54x | 10.19x | -17.41x | 23.05x | 0.58x | |
| Current ratio | 5.01x | 3.69x | 1.04x | 0.98x | 3.40x | |
| Income quality | 3.24x | -0.31x | 0.27x | 0.16x | 1.39x | |
| Graham number | $15 | — | — | — | $53 | |
| Graham net-net | -$7 | -$10 | -$15 | -$17 | -$7 | |
| Tax burden | 63.5% | 133.4% | 104.0% | 96.6% | 72.4% | |
| Interest burden | 58.3% | 273.8% | 435.0% | 200.4% | 78.5% | |
| Working capital | $530.3M | $436.3M | $28.2M | -$18.5M | $895.9M | |
| Invested capital | $1.17B | $1.21B | $993.8M | $1.77B | $2.55B | |
| Return on assets | 4.0% | -13.7% | -41.7% | -6.7% | 7.4% | |
| Operating ROA | 8.1% | -6.8% | -29.1% | -5.6% | 11.7% | |
| Return on tangible assets | 6.0% | -21.5% | -60.5% | -9.5% | 10.3% | |
| Return on equity | 10.1% | -39.5% | -117.1% | -15.2% | 13.6% | |
| Return on invested capital | 5.9% | -8.8% | -45.8% | -5.7% | 9.4% | |
| Return on capital employed | 9.3% | -8.9% | -62.0% | -8.8% | 13.2% | |
| Earnings yield | 8.0% | -37.6% | -618.9% | -35.8% | 9.4% | |
| Free cash flow yield | 23.7% | 7.1% | -209.9% | -25.3% | 4.1% | |
| Capex / Op. cash flow | 8.1% | 39.0% | -25.0% | -339.6% | 70.1% | |
| Capex / Depreciation | 14.4% | 21.0% | 41.2% | 80.8% | 181.7% | |
| Capex / Sales | 1.9% | 2.2% | 4.9% | 10.4% | 12.7% | |
| SG&A / Sales | 25.1% | 28.6% | 34.0% | 30.4% | 19.7% | |
| R&D / Sales | 7.2% | 6.8% | 10.6% | 16.9% | 13.3% | |
| Stock comp / Sales | 2.2% | 1.7% | 2.2% | 4.0% | 2.4% | |
| Intangibles / Total assets | 33.1% | 36.1% | 31.1% | 29.9% | 28.0% | |
| Days sales outstanding | 41d | 54d | 66d | 52d | 57d | |
| Days payables outstanding | 52d | 33d | 59d | 59d | 48d | |
| Operating cycle | 361d | 224d | 241d | 251d | 186d | |
| Cash conversion cycle | 309d | 191d | 181d | 192d | 138d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-06 Emergent Biosolutions (EBS) Soars 14.4%: Is Further Upside Left in the Stock? Emergent Biosolutions (EBS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 2026-10-05 Russian plague outbreak could boost these under-the-radar pharma stocks Global biosecurity alarms are flashing after an incident at an anti-plague research facility in Siberia sparked a severe public health response. Following the fatal lab exposure of a researcher in Irkutsk region to Yersinia pestis – the bacterium causing pneumonic plague – Russian officials placed several regional hospitals under quarantine and isolated nearly 200 contacts.
- 2026-10-05 Emergent Biosolutions (NYSE:EBS) Stock: Insider Paul Anthony Williams Sells 3,000 Shares Emergent Biosolutions Inc. (NYSE: EBS - Get Free Report) SVP Paul Williams sold 3,000 shares of the company''s stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $6.53, for a total value of $19,590.00. Following the completion of the sale, the senior vice president owned 156,098
- 2026-10-05 Emergent Biosolutions Inc. (NYSE:EBS) Stock Has Consensus Price Target of $10.00 Emergent Biosolutions Inc. (NYSE: EBS - Get Free Report) has received an average recommendation of "Hold" from the six analysts that are currently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and three have given a buy recommendation to the company.
- 2026-09-28 Contrasting Emergent Biosolutions (NYSE:EBS) and Coherus Oncology (NASDAQ:CHRS) Coherus Oncology (NASDAQ: CHRS - Get Free Report) and Emergent Biosolutions (NYSE: EBS - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership and earnings. Analyst Ratings This is a breakdown of
- 2026-09-24 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. ("Emergent" or the "Company") (NYSE: EBS).
- 2026-09-22 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. (“Emergent” or the “Company”) (NYSE: EBS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
- 2026-09-17 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. ("Emergent" or the "Company") (NYSE: EBS).
- 2026-09-15 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. (“Emergent” or the “Company”) (NYSE: EBS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
- 2026-09-15 Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility CANTON, Mass., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a ribbon cutting ceremony on Wednesday, September 16 at 10 a.m. ET to celebrate the manufacturing restart and growth of its Canton, Massachusetts facility and the company''s investment in the future of advanced biopharmaceutical manufacturing in the Commonwealth.